Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis
Mohamed Elsaid, Veterinary Surgeon at Canadian Veterinary Hospital, shared on LinkedIn:
”Hyperlipidemia in Cushing’s Syndrome and Its Role in Thrombogenesis
Hyperlipidemia is a common but often underestimated metabolic consequence of Cushing’s syndrome, and it plays a direct role in the development of thromboembolic disease.
Pathophysiology
Chronic hypercortisolism induces dyslipidemia through multiple mechanisms:
- Increased hepatic VLDL synthesis
- Enhanced lipolysis with redistribution of free fatty acids
- Reduced activity of lipoprotein lipase
- Insulin resistance contributing to altered lipid metabolism
This typically results in:
– Marked hypertriglyceridemia
– Elevated total cholesterol
– Lipemic or grossly turbid serum samples (as seen clinically)
– Link Between Hyperlipidemia and Thrombosis
Hyperlipidemia contributes to thrombogenesis by:
- Increasing blood viscosity
- Promoting endothelial dysfunction
- Enhancing platelet activation and aggregation
- Reducing fibrinolytic activity via increased PAI-1
- Upregulating procoagulant factors (Factors VIII, IX, XI)
These effects act synergistically with cortisol-induced:
Antithrombin III suppression
Decreased protein C and S activity
The result is a profound hypercoagulable state.
Clinical Implications
Patients with Cushing’s syndrome are predisposed to:
Venous thromboembolism (VTE)
Pulmonary thromboembolism
Microthrombi affecting renal, hepatic, and pulmonary perfusion
Hyperlipidemia should therefore be viewed as a pathologic contributor, not merely a biochemical abnormality.
Clinical Take-Home Messages
– Lipemic serum in Cushing’s patients is a red flag
– Routine lipid profiling should be part of endocrine case monitoring
– Thrombotic risk assessment is essential, especially in severe or untreated cases
– Early intervention may reduce morbidity and mortality.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy